CLAIMS

1. A tablet formulation comprising AG10, or a pharmaceutically acceptable salt thereof, and one or more fillers, wherein

(a) said tablet formulation comprises at least 40% or more by weight of AG10 or a pharmaceutically acceptable salt thereof; and

(b) said one or more fillers comprise a high-grade microcrystalline cellulose characterized by cellulose polymers with (i) spherical morphology and porous structure or (ii) needle-like particle shape.

2. The tablet formulation of claim **1**, comprising about 40-85% by weight of AG10 or a pharmaceutically acceptable salt thereof.

3. The tablet formulation of claim **2**, comprising about 50-75% by weight of AG10 or a pharmaceutically acceptable salt thereof.

4. The tablet formulation of claim **1**, comprising about 50% by weight of AG10 or a pharmaceutically acceptable salt thereof.

5. The tablet formulation of claim **1**, comprising about 66.7% by weight of AG10 or a pharmaceutically acceptable salt thereof.

6. The tablet formulation of claim **1**, comprising about 75% by weight of AG10 or a pharmaceutically acceptable salt thereof.

7. The tablet formulation of claim **1**, wherein said one or more fillers comprise about 1-60% by weight of said tablet formulation.

8. The tablet formulation of claim **7**, wherein said one or more fillers comprise about 5-55% by weight of said tablet formulation.

9. The tablet formulation of claim **7**, wherein said one or more fillers comprise about 10-50% by weight of said tablet formulation.

10. The tablet formulation of claim **7**, wherein said one or more fillers comprise about 15-45% by weight of said tablet formulation.

11. The tablet formulation of claim **1**, wherein said one or more fillers further comprise a cellulose derivative or an inorganic salt.

12. The tablet formulation of claim **1**, wherein said one or more fillers further comprise silicon dioxide.

13. The tablet formulation of claim **1**, further comprising one or more disintegrants, said one or more disintegrants comprise about 1-15% by weight of said tablet formulation.

14. The tablet formulation of claim **13**, wherein said one or more disintegrants comprise about 3-8% by weight of said tablet formulation.

15. The tablet formulation of claim **13**, wherein said one or more disintegrants comprise about 6% by weight of said tablet formulation.

16. The tablet formulation of claim **13**, wherein said one or more disintegrants comprise croscarmellose sodium.

17. The tablet formulation of claim **1**, further comprising one or more lubricants, said one or more lubricants comprise about 0.1-8% by weight of said tablet formulation.

18. The tablet formulation of claim **17**, wherein said one or more lubricants comprise about 1.5% by weight of said tablet formulation.

19. The tablet formulation of claim **17**, wherein said one or more lubricants comprise magnesium stearate.

20. The tablet formulation of claim **1**, wherein said tablet formulation is at least 75% dissolved after performance of a dissolution test in a solution of 0.1N HCl at 37±0.5 ºC in an Apparatus-II (Paddles) with a paddle speed of about 50 rpm for 10 minutes.


21. The tablet formulation of claim **20**, wherein said tablet formulation is at least 85% dissolved after performance of said dissolution test.

22. The tablet formulation of claim **21**, wherein said tablet formulation is at least 95% dissolved after performance of said dissolution test.

23. The tablet formulation of claim **20**, wherein said dissolution test is performed at least three months after preparation of said tablet formulation.

24. The tablet formulation of claim **1**, further comprising a coating agent.

25. The tablet formulation of claim **1**, wherein AG10 is the pharmaceutically acceptable salt form of Formula Ia



(Ia).

26. A tablet formulation comprising at least 40% or more by weight of AG10, or a pharmaceutically acceptable salt thereof; a high-grade microcrystalline cellulose filler; an inorganic salt filler; a disintegrant; and a lubricant, wherein

said high-grade microcrystalline cellulose is characterized by cellulose polymers (i) with spherical morphology and porous structure or (ii) needle-like particle shape